НАУКА О ЛЕКАРСТВЕННЫХ ШЛЯПОЧНЫХ ГРИБАХ: СОВРЕМЕННЫЕ ПЕРСПЕКТИВЫ, ДОСТИЖЕНИЯ, ДОКАЗАТЕЛЬСТВА И ВЫЗОВЫ

C.П. Вассер

Аннотация


В обзоре представлены достижения, перспективы, проблемы и пути развития науки о лекарственных шляпочных грибах в XXI веке. Для лекарственных шляпочных и других макроскопических грибов известно около 130 фармакологических применений, включая противоопухолевое, иммуномодулирующее, антиоксидантное, связывающее свободные радикалы, кардиоваскулярное, снижающее холестерин в крови, противовирусное, антибактериальное, противопаразитное, противогрибковое, детоксифицирующее, гепатопротекторное и противодиабетическое действие. У базидиомицетов биологически активные вещества содержатся не только в плодовых телах, но также в мицелии и культуральной жидкости. Особое внимание в обзоре уделено грибным полисахаридам и вторичным метаболитам. Обобщены результаты исследований полисахаридов из примерно 700 видов высших гетеро- и гомобазидиомицетов. Описаны многочисленные выделенные из лекарственных грибов биологически активные полисахариды и полисахаридо-протеиновые комплексы, способные стимулировать иммунные реакции, а также обладающие выраженной противоопухолевой активностью. Механизм такого действия полностью не раскрыт, и в центре внимания находятся вопросы стимулирования и модуляции иммунного ответа этими соединениями. Некоторые из них прошли фазы I, II и III клинических испытаний, и широко и успешно применяются в Азии для лечения различных видов рака и других заболеваний. В обзоре также отмечены нерешенные вопросы исследования медицинского применения шляпочных грибов.

Ключевые слова


лекарственные грибы, антиоксидантная активность, полисахариды, β-глюканы, противоопухолевая активность, иммуномодулирующее действие, вторичные метаболиты.

Полный текст:

PDF

Как процитировать материал

Литература


Reshetnikov S.V., Wasser S.P., Tan K.K. Higher Basidiomycota as source of antitumor and immunostimulating polysaccharides. Int J Med Mushrooms. 2001;3:361-94.

Van Griensven L.J.L.D. Culinary-medicinal mushrooms: must action be taken. Int J Med Mushrooms. 2009;11:281-86.

Wasser S.P. Medicinal mushroom science: history, current status, future trends, and unsolved problems. Int J Med Mushrooms. 2010;12(1):1-16.

Chang S.T., Wasser S.P. The role of culinarymedicinal mushrooms on human welfare with a pyramid model for human health. Int J Med Mushrooms. 2012;1:95-134.

Pöder R. The Ice man’s fungi: facts and mysteries. Int J Med Mushrooms. 2005;7:357-59.

Wasson R.G. Soma. Divine Mushroom of Immortality. Harcourt Brace Jovanovich, Inc. NY, 1968.

Hyde K.D., Bahkali A.H., Moslem M.A. Fungi – an unusual source for cosmetics. Fungal Diversity. 2010;43:1-9.

Lindequist U. The merit of medicinal mushrooms from a pharmaceutical point of view. Int J Med Mushrooms. 2013;15(6):517-23.

Hawksworth D.L. Mushrooms: the extent of the unexplored potential. Int J Med Mushrooms. 2001;3:333-40.

Hawksworth D.L. Global species number of fungi: are tropical studies and molecular approaches contributing to a more robust estimate? Biodivers Conserv. 2012;21:2425-33.

Kirk P.M., Cannon P.F., David J.C., Stalpers J.A. Ainsworth & Brisby’s Dictionary of the Fungi. 10th ed. CAB International, Wallingford, 2008.

Blackwell M. The fungi:1,2,3…5.1 million species? Am J Bot. 2011;98(3):426-38.

Bass D., Richards T.A. Three reasons to reevaluate fungal diversity ‘on Earth and in the ocean’. Fungal Bio Rev. 2011;25:159-64.

Hibbett D.S., Taylor J.W. Fungal systematics: is a new age of enlightenment at hand? Nat Rev Microbiol. 2013;11:129-33.

Anke T. Basidiomycetes: a source for new bioactive secondary metabolites. Prog Ind Microbiol. 1989;27:51-66.

Zaidman B.-Z., Yassin M., Mahajna J., Wasser S.P. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol. 2005;67:453-68.

De Silva D.D., Rapior S., Sudarman E., Stadler M., Xu J., Alias S.A., Hyde K.D. Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry. Fungal Diversity. 2013;62:1-40.

Dai Y.-Ch., Yang Z.-L., Ui B.-K., Yu Ch.- J., Zhou L.-W. Species diversity and utilization of medicinal mushrooms and fungi in China (review). Int J Med Mushrooms. 2009;11:287-302.

Lo H.-Ch., Wasser S.P. Medicinal mushrooms for glycemic control in diabetes mellitus: history, current status, future perspectives, and unsolved problems (review). Int J Med Mushrooms, 2011;13(5):401-26.

Didukh M.Y., Wasser S.P., Nevo E. Medicinal value of species of the family Agaricaceae Cohn (higher Basidiomycetes): Current stage of knowledge and future perspectives. Int J Med Mushrooms. 2003;5:133-52.

Chihara G., Hamuia J., Maeda Y.Y., Arai Y., Fukuoka F. Fractionation and purification of the polysaccharides with marked antitumour activity especially lentinan from Lentinus edodes. Cancer Res. 1970;30:2776-81.

Zhang M., Cui S.W., Cheung P.C.K., Wang Q. Antitumor polysaccharides from mushrooms: a review on their isolation, structural characteristics and antitumor activity. Trends Food Sci Technol. 2007;18:4-19.

Zhang Y., Li Sh., Wang X., Zhang L., Cheung P.C.K. Advances in lentinan: isolation, structure, chain conformation and bioactivities. Food Hydrocolloids. 2011;25:1996-2006.

Zhang Y., Kong H., Fang Y., Nishinan K., Phillips G.O. Schizophyllan: a review on its structure, properties, bioactivities and recent development. Bioactive Carbohydrates and Dietary Fiber. 2013;1(1):53-71.

Lee D.H., Kim H.W. Innate immunity induced by fungal b-glucans via dectin-1 signaling pathway. Int J Med Mushrooms. 2014;16(1):1-16.

Barillot E., Calzone L., Hupe Ph., Vert J.- Ph., Zinovyev A. Computation System Biology of Cancer. CRC Press, Taylor & Francis Group. A Chapman & Hall Book; 2013.

Stewart B.W., Wild Ch.P., eds. World Cancer Report 2014. Lyon: International Agency for Research on Cancer; 2014.

Mizuno T. The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan (Review). Int J Med Mushrooms. 1999;1:9-29.

Hobbs Ch.R. Medicinal value of Lentinus edodes (Berk.) Sing. (Agaricomycetideae). A literature review. Int J Med Mushrooms. 2000;2:287-302.

Zhuang C., Wasser S.P. Medicinal value of culinary-medicinal Maitake mushroom Grifola frondosa (Dicks.:Fr.) S.F. Gray (Aphyllophoromycetideae). Review. Int J Med Mushrooms. 2004;6:287-313.

Boh B, Berivic M. Grifola frondosa (Diks.:Fr.) S.F. Gray (Maitake mushroom): medicinal properties, active compounds, and biotechnological cultivation. Int J Med Mushrooms. 2007;9:89-108.

Hobbs Ch.R. The chemistry, nutritional value, immunopharmacology, and safety of the traditional food of medicinal split-gill fungus Schizophyllum commune Fr.:Fr. (Aphyllophoromycetideae). A literature review. Int J Med Mushrooms. 2005;7:127-40.

Lin Z.-B. Lingzhi. From Mystery to Science. Peking University Press. 2009.

Mahajna J., Dotan N., Zaidman B.-Z., Petrova R.D., Wasser S.P. Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum. Nutrition and Cancer. 2010;61:16-26.

Hobbs Ch.R. Medicinal value of Turkey Tail fungus Trametes versicolor (L.:Fr.) Pilát (Aphyllophoromycetideae). Int J Med Mushrooms. 2004;6:195-218.

Mizuno T., Zhuang, Abe K., Okamoto H., Kiho T., Ukai Sh., Leclerc S., Meijer L. Antitumor and hypoglycemic activities of polysaccharides from the sclerotia and mycelia of Inonotus obliquus (Pers.:Fr.) Pil. (Aphyllophoromycetideae). Int J Med Mushrooms. 1999;1:301-316.

Balandykin M.E., Zmitrovich I.V. Review on Inonotus obliquus (Basidiomycota). Realm on medicinal applications and approaches on resources estimation. Int J Med Mushrooms. 2015;17(2):95- 104.

Hsieh P.-W., Wu J.-B., Wu Y.-Ch. Chemistry and biology of Phellinus linteus. BioMed. 2013;3:106-13.

Maruyama H., Ikekawa T. Immunomodulation and antitumor activity of a mushroom product, proflamin, isolated from Flammulina velutipes (W.Curt.:Fr.) Singer (Agaricomycetideae). Int J Med Mushrooms. 2007;9:109-22.

Matsuzawa T. Studies on antioxidant effects of culinary-medicinal bunashimeji mushroom Hypsizygus marmoreus (Peck) Bigel. (Agaricomycetidae). Int J Med Mushrooms. 2006;8(3):245-50.

Holliday H., Cleaver M. Medicinal value of the caterpillar fungi species of the genus Cordyceps (Fr.) Link (Ascomycetes). A review. Int J Med Mushrooms. 2008;10:209-18.

Wasser S.P., Didukh M.Y., Amazonas M.A.L.A., Nevo E., Stamets P., Eira A.F. Is widely cultivated culinary-medicinal Royal Sun Agaricus (the Himematsutake mushroom) indeed Agaricus blazei Murrill? Int J Med Mushrooms. 2002;4:267-90.

Wasser S.P., Didukh M.Y., Amazonas M.A.L.A., Nevo E., Stamets P., Eira A.F. Is a widely cultivated culinary-medicinal Royal Sun Agaricus (Champignon do Brazil, or the Himematsutake mushroom) Agaricus brasiliensis S.Wasser et al. indeed a synonym of A. subrufescens Peck? Int J Med Mushrooms. 2005;7:507-11.

Lachter J., Yampolsky Y., Gafni-Schieber R., Wasser S.P. Yellow brain culinary-medicinal mushroom, Tremella mesenterica Ritz.: Fr. (Higher Basidiomycetes), is subjectively but not objectively effective for eradication of Helicobacter pylori; a prospective controlled trial. Int J Med Mushrooms. 2012;14 (1):55-63.

Yassin M., Wasser S.P., Mahajna J. Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl. Int J Oncol. 2008;32:1197-1204.

Petrova R.D., Mahajna J., Wasser S.P. et al. Marasmius oreades substances block NF-kappaB activity through interference with IKK activation pathway. Mol Biol Rep. 2009;36:737-44.

Rouhana-Toubi A., Wasser S.P., Fares F. Ethyl acetate extracts of submerged cultured mycelium of higher Basidiomycetes mushrooms inhibit human ovarian cancer cell growth. Int J Med Mushrooms. 2009;11: 29-37.

Dotan N., Wasser S.P., Mahajna J. The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator. Integrative Cancer Therapies. 2011;10(2):148-59.

Ruimi N., Petrova R.D., Agbaria R., Sussan S., Wasser S.P., Reznick A.Z., Mahajna J. Inhibition of TNFα-induced iNOS expression in HSVtk transduced 9L glioblastoma cell lines by Marasmius oreades substances through NF-κB- and MAPK-dependent mechanisms. Mol Biol Rep. 2010;37:3801-12.

Ruimi N., Rwashdeh H., Wasser S.P., Konkimalia B., Efferth T., Borgatti M., Gambari R., Mahajna J. Daedalea gibbosa substances inhibit LPS-induced expression of iNOS by suppression of NF-κB and MAPK activities in RAW 264.7 macrophage cells. Int J Mol Med. 2010;25:421-32.

Boh B. Ganoderma lucidum: a potential for biotechnological production of anti-cancer and immunomodulatory drugs. Recent Patents on Anticancer Drug Discovery. 2013;8:255-87.

Wasser S.P., Zmitrovich I.V., Didukh M.Y., Spirin W.A., Malysheva V.F. Morphological Traits of Ganoderma lucidum Complex Highlighting G. tsugae var. jannieae: The Current Generalization. Ruggell, Liechtenstein, A.R.A. Gantner Verlag K.G; 2006.

Moncalvo J.-M., Rivarden L. A nomenclatural study of the Ganodermataceae Donk. Synopsis Fungorum. 1997;11:1-114.

Zhao J.-D. The Ganodermataceae in China. Bibliotheca Mycologica Ser. 132. Berlin, Stuttgart: J. Cramer; 1989.

Cao Y., Wu Sh.-H., Dai Yu.-Ch. Species clarification of the prize medicinal Ganoderma mushroom “Lingzhi”. Fungal Diversity. 2012;56:49-62.

Yang Z.L., Feng B. What is the Chinese “Lingzhi”? – a taxonomic mini-review. Mycology. 2013;4(1):1-4.

Chen Sh., Xu J., Liu Ch. et al. Genome sequence of the model medicinal mushroom Ganoderma lucidum. Nate Communications 2012;3:913/DOI:10.10/ncomms192338.

Kerrigan R. Agaricus subrufescens, a cultivated edible and medicinal mushroom, and its synonyms. Mycologia. 2005;97:12-24.

Wasser S.P. Molecular identification of species of the genus Agaricus. Why should we look at morphology? Int J Med Mushrooms. 2007;9:85-8.

Buchalo A.S., Mykchaylova O., Lomberg M., Wasser S.P. Microstructures of vegetative mycelium of macromycetes in pure culture. Kiev: Alterpress; 2009.

McKenna D.J., Jones K., Hughes K., Humphrey Sh. Botanical Medicines. The Desk Reference for Major Herbal Supplements. 2nd edn. NY, London, Oxford: The Haworth Herbal Press; 2002.

Deng G., Lim H., Seidman A. et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol. 2009;135:1215-21.

Ishibashi K.I., Dogasaki C., Iriki T., Motoi M., Kurone Y.I., Miura N.N., Adachi L.S., Ohno N. Anti-β-glucan antibody in bovine sera. Int J Med Mushrooms. 2005;7:513.

Li JW.-H., Vederas J.C. Drug discovery and natural products: end of an era or an endless frontier. Science. 2009;325:161-5.

Ammerpohl O., Tiwari S., Kalthoff H. Target gene discovery for novel therapeutic agents in cancer treatment. Methods Mol Biol. 2010;576:42745.

Pollack A. Drug firms see fortune in treating cancer. Int Herald Tribune. 2009;15-6.

Endo A. The origin of the statins. Int Congress Series. 2004;1262:3-8.

Chen J., Seviour R. Medicinal importance of fungal β–(1-3), (1-6)-glucans. Mycol Res. 2007;111:635-52.

Ohno N. Structural diversity and physiological functions of β–glucans. Int J Med Mushrooms. 2005;7:167-73.

Miller H., Zhang J., Kuo Lee R., Patel G.B., Chen W. Intestinal M cells: the fallible sentinels? World J Gastroenterol. 2007;14:1477-86.

Pamer E.G. Immune responses to commensal and environmental microbes. Nat Immunol. 2007;8:1173-78.

Lehmann J., Kunze R. Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system. US Patent 2000; 6143883.

Tada R., Adachi Y., Ishibashi K-I., Tsubaki K., Ohno N. Binding capacity of a barley β-Dglucan to the b-glucan recognition molecule Dectin-1. J Agr Food Chem. 2008;56:1442-50.

Tiwari U., Cummins E. Factors influencing beta-glucan levels and molecular weight in cereal-based products. Cereal Chem. 2009;86:290-301.

Liu J.J., Gunn L., Hansen R., Yan J. Combined yeast-derived beta glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exper Mol Pathol. 2009;86:208-14.

Taylor P.R., Tsoni S.V., Willment J.A. et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31-8.

Harada T., Ohno N. Dectin-1 and GM- CSF on immunomodulating activities of fungal 6-branched 1,3-b-glucans. Int J Med Mushrooms. 2008;10:101-4.

Graham L.M., Brown G.D. The Dectin-2 family of C-type lectins in immunity and homeostasis. Cytokine. 2009;48:148-55.

Falch B.H., Espevik T., Ryan L., Stokke B.T. The cytokine stimulating activity of (1-3)-betaD-glucans is dependent on the triple helix conformation. Carbohydr Res. 2000;329:587-96.

Park H.-G., Shim Y.Y., Choi S.-O., Park W.- M. New method development for nanoparticle extraction of water-soluble β-(1-3)-D-glucan from edible mushrooms, Sparassis crispa and Phellinus linteus. Agricultural and Food Chem. 2009; 57:2147-54.

Nitschke J., Modick H., Busch M., Wantoch R., Wantoch von Rekowski R., Albenbach H.- J., Mölleken H. A new colorimetric method to quantify β-1,3-1,6-glucans in comparison with total β-1,3-glucans in edible mushrooms. Food Chem. 2011;127:791-6.

Khamaisie H., Sussan S., Tal M., Najajren Y., Rurhardt M., Mahajna J. Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity. Anticancer Res. 2011;31:177-4.

Sharvit L.E., Wasser S.P., Fares F. The effect of culture liquid ethyl acetate mycelium extracts of medicinal mushrooms on the viability of human pancreatic cancer cells. Int J Med Mushrooms. 2012;14 (2):169-80.

Roberts R.M., Smith G.W., Bazer F.W. et al. Farm animal research in crisis. Science. 2009;324:468-9.

Jong Sh.-J. Protecting intellectual property assets of mushroom genetic resources for invention and innovation. Int J Med Mushrooms. 2005;7 (3):348-9.




DOI: http://dx.doi.org/10.24855/biosfera.v7i2.63

© ФОНД НАУЧНЫХ ИССЛЕДОВАНИЙ "XXI ВЕК"